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Abstract
This case report looks at a middle aged woman with a traumatic brain injury (TBI) from a
domestic assault and subsequent behavioral disturbances that required medication management.
There are no current guidelines on what to use to treat agitation and aggression related to TBI’s,
so a literature review was done to look at research for treatment of this situation. Neuroleptic
medications were utilized with varying effectiveness; however, the literature review
contraindicates this class of medication as it can delay cognitive recovery based on limited
human studies. Other medications are discussed in various articles, but there are no current FDA
approved medications for behavioral disturbances in patients suffering from TBI’s.
Environmental modifications are noted to be the most effective method of reducing behavioral
disturbances by multiple articles.
Keywords: traumatic brain injury, post-traumatic agitation, aggression, pharmacologic
management
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Pharmacologic treatment of agitation in traumatic brain injuries
Traumatic brain injuries (TBI) can be a devastating event to occur to any individual with
lasting changes that can affect both the individual in question and those who are a part of their
life. Part of healing from a TBI includes recovering from post-traumatic amnesia, delirium and
associated complications; some of which include depression, anxiety, sleep disturbances and
agitation. According to Segal (2017), three main areas that are affected by neuropsychiatric
sequelae are cognition, emotions, and behaviors. According to Oyesanya, Bowers, Royer, and
Turkstra (2018), major concerns of treating patients with TBI’s reported by nursing staff
surveyed was worry about causing no additional harm to the patient, but also preventing harm to
staff and family as violence and impulsivity can be unpredictable with this population of
patients. Family members may have no idea how to manage this change in behavior from their
loved one, so nursing staff and providers need to have a good idea of how to educate both patient
and family regarding treatment of the aggression and impulsivity with environmental factors and
pharmacological methods. When a provider is looking at interventions to help with those posttraumatic complications, they need to consider the injury the brain incurred and how medications
might affect cognitive recovery.
Background
This literature review will look at a single case report of a patient who suffered a
traumatic brain injury and had significant neuropsychiatric sequelae, including episodes of
agitation to see how the patients care could have been improved or changed or if the
interventions used were appropriate in the patient’s specific situation. There are many ways that
a person can incur a traumatic brain injury, all of which cause lasting after effects physically and
mentally and can drastically change someone’s quality of life going forward.
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Depression is noted to be the most common complication from a TBI, as those affected
are four times more likely to attempt suicide than the general population, usually within the first
five years (Segal, 2017). There is also an increased risk of developing other mental health
conditions; there is a five point three times increased risk of developing bipolar disorder, a five
point eight times increased risk of post-traumatic stress disorder and/or panic disorder, and two
point three times increased risk of generalized anxiety disorder. It is also noted by Segal (2017)
that one-third to one-half of patients with TBI’s also are affected by personality changes
including apathy, emotional lability, increased impulsivity and decreased judgement skills.
These personality changes can lead to an increased risk of agitation or aggression. Add on the
risk factors that indicate even further potential of aggression that include premorbid affective
disorders, substance abuse, personality disorders and frontal lobe injury from the traumatizing
event and it becomes apparent that agitation and aggression is something that needs to be
addressed early to ensure therapeutic interventions are utilized.
Case Report
The patient that is presented in this case report is a fifty-year-old woman who was
physically assaulted in her apartment by an unknown assailant. Per the emergency room report,
neighbors had heard screaming and items being broken in the apartment and called 911 for a
possible domestic abuse situation. The patient was found by EMS lying on her back with a
laceration over her left eye and was only responsive to painful stimuli with slurring speech. It
was noted by EMS that there were multiple broken windows, furniture and alcohol containers
strewn around the apartment. The patient had a Glasgow Coma Score of ten at time of EMS
intervention, and needed to be restrained on the cart as she was attempting to pull at medical
equipment.
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According to the patient’s mother, the patient had a history of borderline personality
disorder, adjustment disorder with mixed anxiety and depressed mood, major depressive disorder
with psychosis, substance abuse concerns including use of alcohol, cocaine and marijuana laced
with embalming fluid and apparently had been experiencing auditory and visual hallucinations
throughout her life but had not had consistent psychiatric care nor was consistent with taking
medications. Previous psychiatric medication trials included citalopram, trazodone, aripiprazole,
quetiapine and lithium; according to the patient’s mother, the patient did very well when on
lithium.
A copy of one of the initial emergency room nurse notes is as follows:
[Female patient] presents after an assault. Struck multiple times in left forehead and
side of head with unknown object. Mostly somnolent, arousable to stimuli.
Arousable to physical stimuli and muttering incomprehensibly. CT head and C
spine negative on prelim reads. 3 cm laceration above her left eyebrow, not
repaired. Lactate 2.9, getting fluids and tetanus. Plan for sober and re-eval. (medical
chart, July 29, 2018)
The patient was eventually transferred to a medical unit for further examination and
stabilization as she was still somnolent and resisting examination. There was initial concern for
a subarachnoid hemorrhage but that was ruled out on a repeat head CT. Labs indicated that
troponins were negative, liver function tests were normal and did not indicate hepatic
encephalopathy. Differential diagnoses on initial history and physical by medicine physician
indicates acute metabolic toxic encephalopathy and/or TBI, victim of domestic assault, possible
alcohol intoxication, hypokalemia, leukocytosis, and elevated lactate. The psychiatric consult
and neurology consult teams concurred that this was most likely hypoactive delirium secondary
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to trauma, TBI, polysubstance abuse and urinary tract infection (UTI). Differentials considered
for altered mental status included acute stress reaction, cocaine washout, and cognitive decline
secondary to TBI or toxin from marijuana laced with embalming fluid. A lumbar puncture was
obtained with unremarkable results, no indication of encephalopathy noted. An MRI was
attempted but unsuccessful due to patient’s agitation and behaviors. She was treated for her UTI;
hypokalemia and elevated lactate were resolved during her stay on the medical unit. She
continued to have cognitive deficiencies that were thought to be a possible unusual post-TBI
syndrome or related to decompensated mental illness. The medical providers stated that after
patient was medically stabilized she would require inpatient psychiatric care for stabilization of
cognitive and behavioral challenges. She was transferred to inpatient psychiatry on August 9th,
2018 and was noted to be oppositional, hostile, uncooperative, sarcastic and irritable as well as
frequently redirecting questions back to her care team instead of answering them. She had been
started on risperidone 1 mg BID and olanzapine 10 mg at bedtime while on medical to help
mediate the behaviors exhibited with minimal response.
A note from the registered nurse working with the patient on August 12th showed what
type of difficulties the patient was having in day to day life, including how to eat and how to take
care of herself generally at this time.
The [patient] was lying in bed saying "leave me alone" when the staff was attempting to
get her up. This writer and staff took off the covers and assisted her to stand to sit in the
wheelchair. Even though she kept saying no thank you and leave me alone she stood and
then was directed and brought to the lounge where she sat in a chair. A tray was put in
front of her and when staff attempted to help her set up her tray "I don't need any help
leave me alone" She picked up a whole pancake with her hands and ate a bite and threw it
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down. At this point the writer started to cut up the patients pancake and put margarine
and syrup on it and after that she ate everything on her tray. She sat at the table and ate
lunch when it was brought and drank fluids.
She keeps repeating the same things over and over about "Leave me alone" "I don't need
to do anything"
A: Continue to be confused, no insight or she doesn't appears [sic] to understand how to
get up and where to go and even how to put syrup and margarine on her pancakes
R: The patient would not have gotten up to eat or drink if the staff had not gotten her up
despite her protests to eat and drink and she needs very basic instructions on how to get
up and where to go and what to do.
P: Continue on one to one for falls, encourage to be up and eat and drink (medical chart,
August 12, 2018)
Her medications were changed; risperidone and olanzapine were discontinued and
haloperidol 5 mg added, which seemed to be more effective as the patient was out in the milieu
more and engaging more appropriately with staff and providers. She did not appear as overtly
anxious but was noted to still be very preoccupied with returning to her apartment. Upon review
of the case by physical medicine and rehabilitation consultants (PM&R), they recommended
against the use of dopaminergic agents, anticholinergic agents, benzodiazepines, GABA agonists
and sedating agents. PM&R recommended the use of second generation antipsychotics (SGA) or
mood stabilizers for treatment of aggression along with environmental adaptations. The
reasoning for using those medications was because dopaminergic, anticholinergic and other
contraindicated agents are thought to prevent motor and cognitive recovery in animal studies.
Haloperidol was discontinued for the patient after fourteen days of use; risperidone was restarted
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and citalopram added. The provider had added clonazepam to treat the patient’s increased
anxiety and agitation a week after restarting risperidone. Another fourteen days after initiation
of risperidone, haloperidol was restarted and both olanzapine and risperidone discontinued, due
to the significant decompensation of the patient that necessitated her to be placed in restraints
and in seclusion multiple times. The benefit of restarting haloperidol was determined to be
greater than the risks of delaying or reducing the patient’s motor and cognitive recovery. She did
appear to be improving after restarting the haloperidol as she was less anxious, less agitated and
not needing as many interventions by staff members.
Literature Review
Review of the literature included a search in CINAHL and Cochrane Library databases.
There were a variety of articles addressing traumatic brain injuries, post-traumatic stress
disorders, agitation and aggression but the majority of pertinent information addressed in these
articles appeared to be from animal studies as there has been limited quality human studies at this
time. There are also a limited number of articles written in the last eight years to use exclusively
and so articles were reviewed from as far back as 2003, mostly from neurological rehabilitation,
brain injury and medicine journals. There were no discovered pertinent articles found from
psychiatric journals aside from studies about treating dementia related behaviors, which may be
useful for future research as this patient did end up with a discharge diagnosis of moderate
neurocognitive disorder in setting of TBI with behavioral disturbance.
According to the U.S. food and drug administration (FDA) website (2018) and Kalra and
Watanabe (2017), there are no FDA approved medications to treat traumatic brain injuries.
Medications discussed and used in the articles reviewed are all being used off-label for the
subsequent behavioral symptoms occurring from traumatic brain injuries. As there have been
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few studies done on medications for use in agitation or behavioral disturbances related to
traumatic brain injuries, there hasn’t been enough empirical evidence for the FDA to support and
approve a particular medication for use in the clinical setting.
Several of the articles reviewed talked about environmental changes and nursing
management as primary methods to reduce behavioral disturbances and agitation.
Environmental changes would include making the environment low stimulus, having simple
clock faces / large digital clocks available, pictures of loved ones, and providing a consistent
schedule with the least amount of staff changes as possible. According to Mortimer and Berg
(2017), patients with traumatic brain injuries have a lower threshold for stress and frequent
changes, and visitors or high stimulus events can push them into becoming agitated. Mortimer
and Berg (2017) conducted a literature review on agitation in patients with TBI’s, looking
specifically at nursing management. The authors only briefly address the use of pharmacologic
agents in treating agitation in this population, however their literature review should be
considered when treating agitated patients as a lot of the same environmental factors are
mentioned in multiple articles. Providers should look at other reasons why a patient may be
agitated, including assessing for pain that isn’t being addressed or bowel and bladder concerns.
The authors mention using music and aromatherapy as alternative methods of trying to treat
agitation, but there is a need for this to be looked into further as that could become too much
stimulus for some patients to handle.
Park, Williams and Lee (2016) did look into the effect of preferred music vs classical
relaxation music vs no music in patients with severe TBI’s as measured by the Agitated Behavior
Scale (ABS). Despite the small sample size of fourteen patients and limited time frame of
exposure to the stimuli (one hour), preferred music was noted to be more apparent in decreased
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ABS scores post-exposure. The researchers did state that they kept the volume of the music low
as to not overwhelm the patients’ tolerance of sound, as well as limited other sources of noise.
There were no relevant studies found that looked at the effect of aromatherapy on agitation from
TBIs, though some studies did look at how aromatherapy may impact patients with dementia
related behaviors that could be reviewed further in the future.
Eisenberg, Im, Swift and Flanagan (2009) wrote a critical review of the management of
treatment of agitation. At the time of the article, there were no standards of care or guidelines for
clinicians to use when treating patients with TBI’s and many providers were attempting to treat
agitation in patients with modalities from the psychiatric field. This included using psychiatric
medications to attempt to reduce levels of agitation and behaviors in patients. Eisenberg et al.
(2009) are also adamant that the environment these patients are in should be as low stimulus and
consistent as possible. The authors stated that non-pharmacological measures should always be
tried first and to address any underlying factors that may be contributing to agitation such as pain
or confusion. Pharmacological measures can be tricky, as many of the agents that would be used
to reduce agitation and anxiety can actually prolong cognitive recovery in patients.
Benzodiazepines, opiates and first generation antipsychotics (FGA) are included in those
medications that are believed to worsen cognitive recovery. The authors talk about reducing the
number of medications a patient may be taking to try to alleviate side effects that may be
occurring, such as removing prophylactic anticonvulsant medications if possible to do so or
using a medication that can act as both prophylactic anticonvulsant and as a mood stabilizer.
Antipsychotics are highly common for providers to use in acute agitation, though rat
studies indicate a delayed cognitive recovery with use of FGA. This has not been observed when
using second generation antipsychotics (SGA) with the exception of risperidone, which was
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shown to delay cognitive recovery in rats. According to Elovic, Lansang, Li and Ricker (2003),
however, risperidone was one of the most promising SGA for use in treating agitation in patients
with TBI’s. That study did mention that there are limited human trials and most of the
information was obtained from animal studies. The authors did also find that haloperidol and
other FGA’s delayed cognitive recovery however, correlating with the findings of later studies.
A feasibility study being done by Deb et al. (2018) is looking at the effectiveness of risperidone
in post-traumatic agitation. The study was to be completed by October 2018, but new
information about results have not been published yet. The authors were completing a double
blind randomized control trial (RCT) that looked at twelve weeks of treatment with risperidone
versus use of a placebo by using the MOAS scale to measure verbal and physical aggression.
However, limitations of this study include having participants with premorbid psychiatric
conditions excluded.
In 2014, according to Ponsford et al., an international team of researchers and clinicians
called INCOG put out an article with recommendations for management of cognition following a
traumatic brain injury; they had written a chapter specifically looking at post-traumatic amnesia
and delirium. Part of what they also found in their research was that neuroleptic medications
should be avoided as much as possible since they can slow cognitive recovery. These
researchers looked at both risperidone and haloperidol use in rats and found that the rats had a
significantly delayed motor recovery, spatial learning ability and slowed swim speed.
Eisenberg et al. (2009) indicates that tricyclic antidepressants (TCA) are reported to be
very helpful, however selective serotonin reuptake inhibitors (SSRI) have not been quite as
effective with treating agitation. Propranolol has been shown to reduce agitation in the majority
of studies, though this is not shown to be effective in all studies. Neurostimulants such as
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amantadine and methylphenidate are found to help improve cognition as well as agitation in
patients, though these results were still from smaller studies.
Kalra and Watanabe (2017) discussed using mood stabilizers in post-traumatic agitation,
but stated that there is limited evidence in treating this condition. The authors performed a
prospective observational cohort study with 2,130 individuals being reviewed who have been
diagnosed with a TBI. About half of those patients were treated with an anticonvulsant while in
rehabilitation, but there was not strong evidence to establish a clear determination regarding
effectiveness. There was significant inconsistency in the way that post-traumatic agitation was
measured, which should be addressed in future studies.
A double blind RCT was done by Zhang and Wang (2017) that looked at the
effectiveness of methylphenidate in treating agitation related to brain injuries. The study was
thirty weeks long and had thirty-six participants which were divided in a 1:1 ratio. The study
results were found to be consistent with what the authors expected, including decreased mental
fatigue and improved cognitive functional recovery. There was nothing in this study that looked
to see if methylphenidate had any effect on agitated behaviors with the patients. It could be
hypothesized that improved cognitive function would correlate with decreased agitation and
behaviors, but it has not been determined by any studies at this point.
A historic cohort study in 2004 by Harmsen, Geurts, Fasotti and Bevaart looked at sixty
patient files over a five and a half-year period in a rehabilitation center to see if there were any
patterns in the use of neuroleptic medications for treatment of agitation. Of the sixty patient files
reviewed, twenty-eight patients had post-traumatic amnesia and sixteen had positive behavioral
disturbances. Seven patients received neuroleptic medications to treat the positive behavioral
disturbances, however five of those seven had significant extrapyramidal symptoms or lab
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abnormalities that required the discontinuation of those medications. For many of the patients, it
was noted by the authors that environmental changes and/or swapping to non-neuroleptic
behavior modifying medications eliminated the need for neuroleptic medication treatment of
behavioral disturbances over a period of about three weeks. Three of the drugs mentioned that
seemed to have a positive impact on reducing behavioral disturbances were amantadine,
mirtazapine and propranolol.
Mysiw et al. (2009) looked at the impact of acute care medications and how they effected
the recovery of patients with traumatic brain injuries. What the authors had found was that if a
patient had post-traumatic amnesia, there was generally a longer period of time to clear if they
were also taking neuroleptic or narcotic medications. This was talked about frequently in
various articles as narcotics, benzodiazepines and neuroleptics are some of the most common
medications prescribed for this patient population. The authors did have findings that supported
the use of stimulants such as amphetamine for increasing recovery time, as well as finding that
the use of antidepressants may help improve recovery.
In the case report being looked at earlier in the paper, it appeared that the providers tried
to do the right things. They had initially utilized SGA’s before going to a FGA, obtained
consults from rehab providers and attempted to re-utilize smaller doses of the medications found
to be safer for cognitive recovery such as olanzapine, risperidone, and citalopram. The patient
was not responding to these medications well and in fact was becoming so confused and agitated
that she ended up in restraints or seclusion multiple times. There were not any charted attempts
to use beta-blockers or amphetamines, which could have been explored to reduce anxiety and
promote cognitive recovery. Looking at the response of the medications compared to the risk of
delaying cognitive recovery when it comes to patient and staff safety as well as the patient’s
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quality of care is extremely important to keep in mind when it comes to developing treatment
plans. Compounding the problem in this case report was that the patient ended up on an
inpatient psychiatric floor, where the milieu could be loud and disruptive. This patient would
have potentially been better suited for a rehabilitation unit that could have done more to utilize
environmental factors to try and reduce behaviors, but she was not medically complex enough
and had gotten rejected for placement at several rehabilitation facilities. She also needed a
locked unit as she was disorganized and disoriented and may have tried to elope from an
unlocked rehab unit or facility.
Implications
Looking at the information gathered from the literature review, there are many factors to
keep in mind for pharmacologic treatment of agitation in patients with TBI’s. Most important is
making sure to evaluate and treat any underlying issues that may be contributing to behaviors
such as pain, bladder and bowel issues or other physical complaints. There is also need to ensure
the environment is altered to suit the patient as well as reorient them; this is the first step to
reducing behaviors before utilizing medications. If the environment is calm, consistent and
appropriate, there are multiple research studies showing that there may be less need for
medications. First line medication choice should never be neuroleptics or benzodiazepines
unless the patient is in imminent danger of harming themselves or others because of the risk of
delaying their cognitive recovery. Getting ahead of a crisis situation is critical and could mean
using antidepressants, beta blockers and mood stabilizers early in the patient’s treatment in an
attempt to avoid need for neuroleptic use. If neuroleptics are used, SGA are to be used first as
there are less reported side effects that can be significantly detrimental to the recovery of the
patient. There are conflicting reports of what specific medications are effective, but there are
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limited large scale, quality human trials done that would demonstrate consistent patterns of
effectiveness with any pharmacological treatment. The FDA has not approved any medications
for behavioral disturbances in this population and most of what providers and researchers
recommend for off-label use is based on animal studies or case reports done without much
scientific backing or standardization. Guidelines for treating this population are still being
developed and changed as more research is being done; this complicated illness can be tough on
providers, patients and their families but more research needs to be done to expedite recovery
and better preserve patient and caregiver safety.
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